心通医疗预计今年上半年收入同比增长22%-28%

新京报网07-05

新京报讯（记者王卡拉）7月5日，心通医疗发布2024年中期业绩预告，报告期内预计收入2.15亿元-2.25亿元，同比增长22%至28%。报告期内，公司旗下TAVI产品新增进入国内50家医院至合计超过600家。附属公司上海佐心医疗科技有限公司自主研发的AnchorMan左心耳封堵器系统及其导引系统（AnchorMan)在中国正式开启商业化进程，已完成近20个省的挂网和10余个省的挂网申报。今年上半年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449318022?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-05 14:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2449318022","market":"hk","top_or_hot":-1,"title":"心通医疗预计今年上半年收入同比增长22%-28%","media":"新京报网","content":"<div>\n<p>新京报讯（记者王卡拉）7月5日，心通医疗发布2024年中期业绩预告，报告期内预计收入2.15亿元-2.25亿元，同比增长22%至28%。报告期内，公司旗下TAVI产品新增进入国内50家医院至合计超过600家。附属公司上海佐心医疗科技有限公司自主研发的AnchorMan左心耳封堵器系统及其导引系统（AnchorMan)在中国正式开启商业化进程，已完成近20个省的挂网和10余个省的挂网申报。今年上半年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705143934aef81705&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通医疗预计今年上半年收入同比增长22%-28%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通医疗预计今年上半年收入同比增长22%-28%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 14:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705143934aef81705&s=b><strong>新京报网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新京报讯（记者王卡拉）7月5日，心通医疗发布2024年中期业绩预告，报告期内预计收入2.15亿元-2.25亿元，同比增长22%至28%。报告期内，公司旗下TAVI产品新增进入国内50家医院至合计超过600家。附属公司上海佐心医疗科技有限公司自主研发的AnchorMan左心耳封堵器系统及其导引系统（AnchorMan)在中国正式开启商业化进程，已完成近20个省的挂网和10余个省的挂网申报。今年上半年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705143934aef81705&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705143934aef81705&s=b","article_id":"2449318022","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705143934aef81705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2449318022","pubTimestamp":1720161540,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"新京报讯 7月5日，心通医疗发布2024年中期业绩预告，报告期内预计收入2.15亿元-2.25亿元，同比增长22%至28%。报告期内，公司旗下TAVI产品新增进入国内50家医院至合计超过600家。今年上半年，VitaFlow Liberty经导管主动脉瓣膜及输送系统和Alwide Plus球囊扩张导管在俄罗斯和智利等国的商业化带来的海外收入快速增长，VitaFlow Liberty获得CE证书，在部分欧洲国家实现首次销售和植入。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1100":"医疗保健设备","02160":"心通医疗-B","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"Xintong Medical expects revenue to grow by 22%-28% year-on-year in the first half of this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1},"content_text":"新京报讯（记者王卡拉）7月5日，心通医疗发布2024年中期业绩预告，报告期内预计收入2.15亿元-2.25亿元，同比增长22%至28%。报告期内，公司旗下TAVI产品新增进入国内50家医院至合计超过600家。附属公司上海佐心医疗科技有限公司自主研发的AnchorMan左心耳封堵器系统及其导引系统（AnchorMan)在中国正式开启商业化进程，已完成近20个省的挂网和10余个省的挂网申报。今年上半年，VitaFlow Liberty经导管主动脉瓣膜及输送系统（VitaFlow Liberty）和Alwide Plus球囊扩张导管（Alwide Plus）在俄罗斯和智利等国的商业化带来的海外收入快速增长，VitaFlow Liberty获得CE证书，在部分欧洲国家实现首次销售和植入。研发方面，心通医疗第三代TAVI产品VitaFlow Ⅲ在国家药监局的注册有序推行，经导管二尖瓣置换产品的人道主义应用亦持续开展，进一步验证其更多型号的安全性和有效性。校对 赵琳","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449318022"}